Rectify Pharma
Rectify Pharma is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Rectify Pharma.
Rectify Pharma is a company.
Key people at Rectify Pharma.
Key people at Rectify Pharma.
Rectify Pharmaceuticals is a development-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on developing Positive Functional Modulators (PFMs)—oral small-molecule therapeutics that restore and enhance ABC transporter function to treat serious genetic and other diseases mediated by membrane protein dysfunction[1][2][6]. The company targets unmet needs in hepatobiliary diseases like primary sclerosing cholangitis (PSC), cardio-renal-metabolic disorders (e.g., vascular calcification, chronic kidney disease), and neurodegenerative conditions, serving patients with rare and common diseases where current therapies fail to address root causes[4][6]. Its lead program, a dual-targeted ABCB4/BSEP PFM for PSC, is in IND-enabling studies, with a pipeline spanning Phase 1 family selection for ABC transporters and expansion into indications like PBC, NASH, and others; launched with a $100M Series A in 2021, Rectify demonstrates strong early momentum through platform validation and key hires like CMO Pol Boudes in 2024[2][3][6].
Rectify was founded in 2020 by Atlas Venture, with Jonathan Moore, Ph.D., as Chief Scientific Officer, drawing from his experience as a founding scientist at Vertex Pharmaceuticals where he pioneered CFTR-targeted therapies for cystic fibrosis—an ABC transporter family member[2]. Rajesh Devraj, Ph.D., President and CEO and Atlas Venture partner, leads the effort, emphasizing disease-modifying treatments for ABC transporter mutations[2]. The idea emerged from untapped potential in the 48-member ABC transporter superfamily, beyond CFTR, with Atlas seeding the company and co-leading a $100M Series A in October 2021 alongside Omega Funds, Forbion, and Longwood Fund to fund initial human proof-of-concept studies[1][2].
Rectify rides the wave of precision medicine for membrane protein dysfunction, expanding proven CFTR modulation to the broader ABC transporter class amid rising demand for disease-modifying therapies in rare liver diseases (e.g., PSC) and cardio-renal-metabolic epidemics—leading global causes of death[2][4][6]. Timing aligns with advances in small-molecule screening and genetic insights into ABC mutations, fueled by market forces like orphan drug incentives and healthcare burdens from cholestatic/NASH diseases; as the first dedicated ABC player, Rectify influences biotech by validating an untapped superfamily, potentially accelerating similar modulator platforms and partnerships in underserved areas[1][6].
Rectify's platform positions it for near-term milestones like IND filing for its PSC lead and Phase 1 entry, with pipeline expansion into high-burden CRM indications driving value inflection[6]. Trends like AI-accelerated drug discovery and combination therapies for multifactorial diseases (e.g., NASH, CKD) will shape progress, amplifying its influence as a pioneer in ABC modulation—potentially yielding first approvals where none exist today[1][6]. This evolution from stealth launch to clinical contender underscores Rectify's potential to rectify unmet needs in biotech's protein-targeting frontier, restoring hope through functional precision.
